Tranzyme Pharma Announces Positive Phase IIb Results With Its Ghrelin Agonist, TZP-101, For Postoperative Ileus (POI)
Oct 3rd 2008Drug InformationGastroIntestinal / Gastroentorology
Tranzyme Pharma today announced positive Phase IIb results for its first-in-class, highly potent and selective ghrelin agonist, TZP-101, for the management of postoperative ileus (POI). Results demonstrated that TZP-101 was both safe and highly effective in reducing the duration of ileus following surgery in patients undergoing open bowel resection.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
